1
|
Thalambedu N, Ogunsesan Y, Sethi J, Hussain M, Yarlagadda L, Gundarlapalli S, Hadidi SA, Thanendrarajan S, Zangari M, Spencer H, Bailey C, Shaughnessy J, Zhan F, Rico JC, van Rhee F, Schinke C. Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant. Transplant Cell Ther 2023. [PMCID: PMC9899531 DOI: 10.1016/s2666-6367(23)00602-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
2
|
Nucci M, Jenks J, Thompson GR, Hoenigl M, Dos Santos MC, Forghieri F, Rico JC, Bonuomo V, López-Soria L, Lass-Flörl C, Candoni A, Garcia-Vidal C, Cattaneo C, Buil J, Rabagliati R, Roiz MP, Gudiol C, Fracchiolla N, Campos-Herrero MI, Delia M, Farina F, Fortun J, Nadali G, Sastre E, Colombo AL, Pérez Nadales E, Alastruey-Izquierdo A, Pagano L. Do high MICs predict the outcome in invasive fusariosis? J Antimicrob Chemother 2021; 76:1063-1069. [PMID: 33326585 DOI: 10.1093/jac/dkaa516] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2020] [Accepted: 11/13/2020] [Indexed: 12/27/2022] Open
Abstract
BACKGROUND Invasive fusariosis (IF) affects mostly severely immunocompromised hosts and is associated with poor outcome. Since Fusarium species exhibit high MICs for most antifungal agents, this could explain the poor prognosis. However, a clear-cut correlation between MIC and outcome has not been established. OBJECTIVE To evaluate the correlation between MIC and outcome (6 week death rate) in patients with IF. METHODS We performed a multicentre retrospective study of patients with IF who received treatment and had MIC levels determined by EUCAST or CLSI for the drug(s) used during treatment. We compared the MIC50 and MIC distribution among survivors and patients who died within 6 weeks from the diagnosis of IF. RESULTS Among 88 patients with IF, 74 had haematological diseases. Primary treatment was monotherapy in 52 patients (voriconazole in 27) and combination therapy in 36 patients (liposomal amphotericin B + voriconazole in 23). The MIC50 and range for the five most frequent agents tested were: voriconazole 8 mg/L (range 0.5-64), amphotericin B 2 mg/L (range 0.25-64), posaconazole 16 mg/L (range 0.5-64), itraconazole 32 mg/L (range 4-64), and isavuconazole 32 mg/L (range 8-64). There was no difference in MIC50 and MIC distribution among survivors and patients who died. By contrast, persistent neutropenia and receipt of corticosteroids were strong predictors of 6 week mortality. CONCLUSIONS Our study did not show any correlation between MIC and mortality at 6 weeks in patients with IF.
Collapse
Affiliation(s)
- Marcio Nucci
- University Hospital, Universidade Federal do Rio de Janeiro - Rua Prof Rodolpho Paulo Rocco 255, 21941-913 Rio de Janeiro, Brazil
| | - Jeffrey Jenks
- Division of Infectious Diseases and Global Public Health, University of California, San Diego - 9500 Gilman Drive MC 0507 La Jolla, CA, USA
| | - George R Thompson
- Department of Internal Medicine, Division of Infectious Diseases and Department of Medical Microbiology and Immunology, University of California-Davis - 3146 Tupper Hall, 1 Shields Ave., Davis, CA, USA
| | - Martin Hoenigl
- Division of Infectious Diseases and Global Public Health, University of California, San Diego - 9500 Gilman Drive MC 0507 La Jolla, CA, USA.,Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz - Auenbruggerpl. 2, 8036 Graz, Austria
| | - Marielle Camargo Dos Santos
- Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo - Rua Botucatu, 740, 04023-062 - São Paulo, Brazil
| | - Fabio Forghieri
- Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia - Via Università, 4, 41121 Modena, Italy
| | - Juan Carlos Rico
- Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock - 4301 W Markham St, Little Rock, AR 72205, USA
| | - Valentina Bonuomo
- Hematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona - Piazzale Aristide Stefani, 1, 37126 Verona, Italy
| | - Leyre López-Soria
- Servicio de Microbiología, Hospital Universitario Cruces, Barakaldo - Cruces Plaza, S/N, 48903 Barakaldo, Bizkaia, Spain
| | - Cornelia Lass-Flörl
- Division of Hygiene and Medical Microbiology, Medical University of Innsbruck - Christoph-Probst-Platz 1, Innrain 52, A - 6020 Innsbruck, Austria
| | - Anna Candoni
- Division of Haematology, Santa Maria Della Misericordia University Hospital of Udine - Piazzale Santa Maria Della Misericordia, 15, 33100 Udine, Italy
| | - Carolina Garcia-Vidal
- Infectious Diseases Department, Hospital Clinic of Barcelona-IDIBAPS, University of Barcelona - C. de Villarroel, 170, 08036 Barcelona, Spain
| | - Chiara Cattaneo
- Haematology Unit, Spedali Civili di Brescia, Via del Medolo, 2, 25123 Brescia, Italy
| | - Jochem Buil
- Center of Expertise in Mycology Radboud University Medical Center/Canisius-Wilhelmina Hospital - Weg door Jonkerbos 100, 6532 SZ Nijmegen, The Netherlands
| | - Ricardo Rabagliati
- Department of Infectious Diseases, Faculty of Medicine, Pontificia Universidad Católica de Chile - Av Libertador Bernardo O'Higgins 340, Santiago, Región Metropolitana, Chile
| | - Maria Pia Roiz
- Servicio de Microbiología, Hospital Universitario Marqués de Valdecilla - Av. de Valdecilla, 25, 39008 Santander, Cantabria, Spain
| | - Carlota Gudiol
- Department of Infectious Diseases, Bellvitge University Hospital - Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Nicola Fracchiolla
- Unità di Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico - Via della Commenda, 10, 20122, Milano, Italy
| | - Maria Isolina Campos-Herrero
- Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria - Calle Plaza Barranco de la Ballena, s/n, 35010 Las Palmas de Gran Canaria, Las Palmas, Spain
| | - Mario Delia
- Sezione di Ematologia, Dipartimento dell'Emergenza e dei Trapianti d'Organo, Università di Bari - Piazza Umberto I, 1, 70121, Bari, Italy
| | - Francesca Farina
- Hematology and Bone Marrow Transplantation, IRCCS San Raffaele Scientific Institute - Via Olgettina, 60, 20132, Milano, Italy
| | - Jesus Fortun
- Infectious Diseases Department, Hospital Universitario Ramón y Cajal - M-607, km. 9, 100, 28034, Madrid, Spain
| | - Gianpaolo Nadali
- Hematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona - Piazzale Aristide Stefani, 1, 37126 Verona, Italy
| | - Enric Sastre
- Department of Infectious Diseases, Bellvitge University Hospital - Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain
| | - Arnaldo L Colombo
- Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal de São Paulo - Rua Botucatu, 740, 04023-062 - São Paulo, Brazil
| | - Elena Pérez Nadales
- Hospital Universitario Reina Sofia, Universidad de Córdoba - Av. Menendez Pidal, s/n, 14004 Córdoba, Spain
| | - Ana Alastruey-Izquierdo
- Mycology Reference Laboratory, National Centre for Microbiology, Instituto de Salud Carlos III - Ctra. de Pozuelo, 28, 28222 Majadahonda, Madrid, Spain
| | - Livio Pagano
- Istituto di Ematologia, Fondazione Policlinico Universitario A. Gemelli-IRCCS-Università Cattolica del Sacro Cuore - Largo Francesco Vito, 1, 00168 Roma RM, Italy
| |
Collapse
|
3
|
Dare RK, Lusardi K, Pearson C, McCain KD, Daniels B, Van S, Rico JC, Painter J, Lakkad M, Rosenbaum ER, Bariola JR. Clinical Impact of Accelerate PhenoTM Rapid Blood Culture Detection System in Bacteremic Patients. Clin Infect Dis 2020; 73:e4616-e4626. [PMID: 32463864 DOI: 10.1093/cid/ciaa649] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2020] [Accepted: 05/22/2020] [Indexed: 12/26/2022] Open
Abstract
BACKGROUND Accelerate Pheno blood culture detection system (AXDX) provides identification (ID) and antimicrobial susceptibility testing (AST) results within 8h of blood culture growth. Limited data exists regarding its clinical impact. Other rapid platforms coupled with antimicrobial stewardship program (ASP) real-time notification (RTN) have shown improved length of stay (LOS) in bacteremia. METHODS A single-center, quasi-experimental study of adult bacteremic inpatients before/after AXDX implementation was conducted comparing clinical outcomes from 1 historical and 2 intervention cohorts (AXDX and AXDX+RTN). Primary outcome was LOS. RESULTS Of 830 bacteremic episodes, 188 (77%) of 245 historical and 308 (155 AXDX, 153 AXDX+RTN; 65%) of 585 intervention episodes were included. Median LOS was shorter with AXDX (6.3d) and AXDX+RTN (6.7d) compared to historical (8.1d; P=0.001). Achievement of optimal therapy (AOT) was more frequent (93.6% and 95.4%) and median time to optimal therapy (TTOT) was faster (1.3d and 1.4d) in AXDX and AXDX+RTN compared to historical (84.6%, P≤0.001 and 2.4d; P≤0.001) respectively. Median antimicrobial days of therapy (DOT) was shorter in both intervention arms compared to historical (6d each vs 7d; P=0.011). Median LOS benefit was most pronounced in patients with coagulase negative Staphylococcus bacteremia (5.5d and 4.5d vs 7.2d; P=0.003) in AXDX, AXDX+RTN, and historical cohorts respectively. CONCLUSIONS LOS, AOT, TTOT, and total DOT significantly improved after AXDX implementation. Addition of RTN did not show further improvement over AXDX and an already active ASP. These results suggest AXDX can be integrated into healthcare systems with an active ASP even without the resources to include RTN.
Collapse
Affiliation(s)
- R K Dare
- Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - K Lusardi
- Hospital Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - C Pearson
- Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - K D McCain
- Hospital Pharmacy, Wadley Regional Medical Center, Texarkana, TX, USA
| | - B Daniels
- College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - S Van
- College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - J C Rico
- Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - J Painter
- Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - M Lakkad
- Division of Pharmaceutical Evaluation and Policy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA
| | - E R Rosenbaum
- Department of Pathology and Laboratory Services, University of Arkansas for Medical Sciences, Little Rock, AR, USA
| | - J R Bariola
- Division of Infectious Diseases, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| |
Collapse
|
4
|
Nucci M, Shoham S, Abdala E, Hamerschlak N, Rico JC, Forghieri F, Nouér SA, Cappellano P, Solza C, Gonzaga Y, Nadali G, Nucci F, Colombo AL, Albuquerque AM, Queiroz-Telles Filho F, Lima CBL, Arrais-Rodrigues C, Rocha V, Marty FM. Outcomes of patients with invasive fusariosis who undergo further immunosuppressive treatments, is there a role for secondary prophylaxis? Mycoses 2019; 62:413-417. [PMID: 30720902 DOI: 10.1111/myc.12901] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2018] [Accepted: 01/31/2019] [Indexed: 11/28/2022]
Abstract
BACKGROUND Patients treated for invasive aspergillosis may relapse during subsequent periods of immunosuppression and should receive secondary prophylaxis. Little is known about the frequency of relapse and practices of secondary prophylaxis for invasive fusariosis (IF). OBJECTIVES Evaluate practices of secondary prophylaxis and the frequency of relapse in patients who survived IF and were exposed to subsequent periods of immunosuppression. METHODS Multicentre retrospective study of patients with haematological malignancies who developed IF, survived the initial fungal disease period, and were exposed to subsequent periods of immunosuppression. RESULTS Among 40 patients, 35 received additional chemotherapy and developed neutropenia (median, 24 days; range, 4-104), and five received glucocorticoids for the treatment of graft-vs-host disease. Overall, 32 patients received secondary prophylaxis (voriconazole in 24) for a median of 112 days (range, 12-468). IF relapsed in five patients (12.5%): 2/8 (25%) not on prophylaxis and 3/32 (9.4%) receiving prophylaxis. Among 28 patients with disseminated IF, relapse occurred in 2/2 (100%) not on prophylaxis and in 3/26 (11.5%) on prophylaxis (P = 0.03). All patients who relapsed IF died. CONCLUSIONS Patients with IF who survive the initial disease may relapse if exposed to subsequent episodes of immunosuppressive therapies. Secondary prophylaxis should be considered, especially if IF was disseminated.
Collapse
Affiliation(s)
- Marcio Nucci
- Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Shmuel Shoham
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Edson Abdala
- Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
| | | | - Juan Carlos Rico
- Division of Infectious Diseases, Department of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Fabio Forghieri
- Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - Simone A Nouér
- Department of Internal Medicine, University Hospital, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Paola Cappellano
- Division of Infectious Diseases, Department of Medicine, Federal University of São Paulo, Sao Paulo, Brazil
| | - Cristiana Solza
- Hospital Universitário Pedro Ernesto, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
| | - Yung Gonzaga
- Instituto Nacional de Cancer José de Alencar Gomes da Silva (INCA), Rio de Janeiro, Brazil
| | - Giampaolo Nadali
- Hematology Unit, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy
| | - Fabio Nucci
- Department Hematology, Fluminense Federal University, Niterói, Brazil
| | - Arnaldo L Colombo
- Division of Infectious Diseases, Department of Medicine, Federal University of São Paulo, Sao Paulo, Brazil
| | | | | | | | | | | | - Francisco M Marty
- Division of Infectious Diseases, Harvard Medical School, Brigham and Women's Hospital, Boston, Massachusetts
| |
Collapse
|
5
|
Moran G, Yarlagadda N, Susanibar S, Kothari A, Rico JC, Burgess MJ. 1593. Recurrence of Clostridium difficile Infection in Multiple Myeloma Patients Receiving Prophylactic Oral Vancomycin or Oral Metronidazole vs. No Prophylaxis. Open Forum Infect Dis 2018. [PMCID: PMC6253229 DOI: 10.1093/ofid/ofy210.1421] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
Abstract
Background Multiple myeloma (MM) patients are at increased risk of Clostridium difficile infection (CDI) compared with the general population. In prior studies, 12–14% were diagnosed with CDI, and ~16% had recurrent CDI during subsequent treatments. Recent studies have shown that oral vancomycin is effective secondary prophylaxis for the prevention of recurrent CDI in the general population. This retrospective study examined if secondary prophylaxis with oral vancomycin or metronidazole is effective to prevent recurrent CDI in MM patients. Methods MM patients who tested positive for their first episode of CDI from January 2014–December 2016 were included, and the 3 months following the CDI diagnosis was reviewed. Patients who died, and those who did not receive additional chemotherapy or antibiotics during the 3-month review period were excluded. The patients were divided into 3 cohorts: (1) oral vancomycin as secondary prophylaxis, (2) oral metronidazole as secondary prophylaxis, and (3) no C. difficile prophylaxis. Results A total of 110 MM patients with a first episode of CDI were reviewed, six were excluded due to death and four were excluded due to no subsequent chemotherapy or antibiotics. This left 100 patients included for analysis. The median age was 62 years, range 34–81. 92 subjects (92%) had exposure to antibiotics and 76 (76%) received chemotherapy. A total of 38 (38%) received secondary prophylaxis: 16 (42%) with oral metronidazole and 22 (58%) with oral vancomycin. There was no significant difference in recurrent CDI in patients who received any secondary prophylaxis (7/38, 18.4%) and in those who received none (15/62, 24.2%), P = 0.46. Incidence of recurrent CDI in patients receiving oral vancomycin (3/22, 13.6%) was not significantly different from patients receiving oral metronidazole (4/16, 25%), P = 0.56. An analysis of risk factors for recurrent CDI showed no difference in recurrence in patients who received metronidazole vs. vancomycin as treatment for the initial CDI. Similar recurrent CDI occurred in patients who received antibiotics and those who received chemotherapy. Conclusion Secondary prophylaxis with either oral metronidazole or oral vancomycin did not reduce the incidence of recurrent CDI in MM patients. Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Gisele Moran
- College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | | | - Sandra Susanibar
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Atul Kothari
- Division of Infectious Diseases, UAMS, Little Rock, Arkansas
| | | | - Mary J Burgess
- Division of Infectious Diseases, UAMS, Little Rock, Arkansas
| |
Collapse
|
6
|
Kamimoto JJ, Susanibar S, Mohan M, Jenjaroenpun P, Gayathri K, Rico JC, Burgess MJ, Tytarenko R, Emery N, Rosenbaum E, Walker B, Nookaew I, Kothari A. 487. Severity and Clinical Outcomes of Clostridium difficile Infection Based on Toxin B Assay Results. Open Forum Infect Dis 2018. [PMCID: PMC6253691 DOI: 10.1093/ofid/ofy210.496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Background Clostridium difficile infection (CDI) remains a major health problem in the United States. The IDSA guidelines recommend using stool toxin assay as part of a multistep algorithm rather than nucleic acid amplification test (NAAT) alone. However, the clinical significance of toxin negative tests remains a subject of debate. We performed a prospective study in our institution to describe clinical outcomes of CDI based on the results of the stool toxin assay. Methods Our laboratory utilizes a 2-step algorithm, using glutamate dehydrogenase plus detection of toxin B by enzyme immunoassay (EIA) arbitrated by NAAT for testing stool samples submitted for C. difficile testing. The study was conducted between January and December 2017. Patients diagnosed with CDI based on laboratory results were divided into two groups based on toxin B assay results. Shotgun metagenomics was performed directly on stool specimens using Illumina NextSeq in a subset of patients. Chart reviews were performed to assess clinical outcomes. Our primary outcome was incidence of severe CDI and 30-day mortality. Results A total of 2,823 samples were submitted to the laboratory for testing for suspected CDI. Three hundred thirty-eight samples in 290 discrete patients were considered positive using the two step algorithm. Whole genome sequencing was performed on samples from 57 patients (Figure 1). Clinical outcome data were available for 53 patients. Thirty percent were on active chemotherapy. Thirty-four patients were toxin B positive (group 1), 19 were toxin B negative (group 2) by EIA. Hospital onset disease was seen in 10 (27%) of patients in group 1 vs. 7 (37%) in group 2 (P = 0.57). Thirty-day mortality was 3% in toxin positive vs. 5% in toxin negative groups (P = 0.67). Severe CDI was seen in 14 (41%) in group 1 vs. 8 (42%) in group 2 (P = 0.94). NAP 1 strain was detected in 10.5% of patients in group 2. Percentage of C. difficile reads on sequencing in fecal samples in group 1 (0.17%) was not significantly different from group 2 (0.24%) (P = 0.70, Figure 2). Conclusion In our cohort, detection of C. difficile toxin in stool samples was not associated with increased severity of disease. Our cohort has a higher prevalence of patients on active chemotherapy than previously studied cohorts. Bioburden of C. difficile was not significantly different in toxin positive and negative disease. ![]()
![]()
Disclosures All authors: No reported disclosures.
Collapse
Affiliation(s)
- Jorge Jo Kamimoto
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Sandra Susanibar
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Meera Mohan
- Division of Hematology Oncology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Piroon Jenjaroenpun
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Krishnan Gayathri
- Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | | | - Mary J Burgess
- Division of Infectious Diseases, UAMS, Little Rock, Arkansas
| | - Ruslana Tytarenko
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Nicole Emery
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Eric Rosenbaum
- Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Brian Walker
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Intawat Nookaew
- Department of Biomedical Informatics, University of Arkansas for Medical Sciences, Little Rock, Arkansas
| | - Atul Kothari
- Division of Infectious Diseases, UAMS, Little Rock, Arkansas
| |
Collapse
|
7
|
Johnsrud JJ, Srivastava S, Rico JC, Davies FE, Rosenbaum ER, Kothari A. An Enlarging Lung Nodule in an Immunocompromised Host. Clin Infect Dis 2018. [DOI: 10.1093/cid/cix842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Joyce J Johnsrud
- Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock
| | - Shweta Srivastava
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock
| | - Juan Carlos Rico
- Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock
| | - Faith E Davies
- Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock
| | - Eric R Rosenbaum
- Department of Microbiology, University of Arkansas for Medical Sciences, Little Rock
| | - Atul Kothari
- Division of Infectious Diseases, University of Arkansas for Medical Sciences, Little Rock
| |
Collapse
|
8
|
Burgess MJ, Rosenbaum ER, Pritt BS, Haselow DT, Ferren KM, Alzghoul BN, Rico JC, Sloan LM, Ramanan P, Purushothaman R, Bradsher RW. Possible Transfusion-Transmitted Babesia divergens-like/MO-1 Infection in an Arkansas Patient. Clin Infect Dis 2018; 64:1622-1625. [PMID: 28329282 DOI: 10.1093/cid/cix216] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/10/2016] [Accepted: 03/07/2017] [Indexed: 12/27/2022] Open
Abstract
A patient with asplenia and multiple red blood cell transfusions acquired babesiosis infection with Babesia divergens-like/MO-1 organisms and not Babesia microti, the common United States species. He had no known tick exposure. This is believed to be the first transfusion-transmitted case and the fifth documented case of B. divergens-like/MO-1 infection.
Collapse
Affiliation(s)
| | | | - Bobbi S Pritt
- Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota
| | | | | | - Bashar N Alzghoul
- Internal Medicine Residency Program, University of Arkansas for Medical Sciences, and
| | | | - Lynne M Sloan
- Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota
| | - Poornima Ramanan
- Division of Clinical Microbiology, Mayo Clinic, Rochester, Minnesota
| | | | | |
Collapse
|
9
|
Atrash S, Lusardi KT, Rico JC, Banderudrappagari R, Pennisi A, Firwana B, Harris DD, Slatton BT, Arnaoutakis K, Makhoul I. A Quality Improvement project to decrease overuse of vancomycin in an inpatient Hematology/Oncology service. J Clin Oncol 2016. [DOI: 10.1200/jco.2016.34.15_suppl.e18167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Shebli Atrash
- University of Arkansas for Medical Sciences, Little Rock, AR
| | | | | | | | - Angela Pennisi
- University of Arkansas for Medical Sciences, Little Rock, AR
| | - Belal Firwana
- University of Arkansas for Medical Sciences Hematology/Oncology Department, Little Rock, AR
| | - Denese D Harris
- University of Arkansas for Medical Sciences, Little Rock, AR
| | | | | | - Issam Makhoul
- University of Arkansas for Medical Sciences, Little Rock, AR
| |
Collapse
|
10
|
Griffin DO, Metzger M, Poeth K, Deng K, Dharsee A, Rico JC, McGowan J. Malignancies, Particularly B-Cell Lymphomas, Are a Frequent Cause of Mortality in Human Immunodeficiency Virus-1 Patients Despite Highly Active Antiretroviral Therapy. Open Forum Infect Dis 2015; 2:ofv147. [PMID: 26566539 PMCID: PMC4630453 DOI: 10.1093/ofid/ofv147] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2015] [Accepted: 09/16/2015] [Indexed: 11/21/2022] Open
Abstract
Human immunodeficiency virus (HIV)-1-infected individuals are affected by diseases at rates above those of their HIV-negative peers despite the increased life expectancy of the highly active antiretroviral therapy era. We followed a cohort of approximately 2000 HIV-1-infected patients for 5 years. The most frequent cause of death in this HIV-1-infected cohort was malignancy, with 39% of all classified deaths due to cancer. Among the cancer deaths, B-cell lymphomas were the most commonly seen malignancy, representing 34% of all cancer deaths. These lymphomas were very aggressive with a median survival of <2 months from time of diagnosis.
Collapse
Affiliation(s)
- Daniel O Griffin
- Department of Biochemistry and Molecular Biophysics ; Department of Medicine, Division of Infectious Diseases , Columbia University Medical Center ; Department of Medicine-Division of Infectious Disease , Hofstra North Shore-LIJ School of Medicine , Manhasset
| | - Michael Metzger
- Department of Biochemistry and Molecular Biophysics , Howard Hughes Medical Institute, Columbia University Medical Center , New York, New York
| | - Kaitlin Poeth
- Department of Medicine-Division of Infectious Disease , Hofstra North Shore-LIJ School of Medicine , Manhasset
| | - Kathy Deng
- Department of Medicine-Division of Infectious Disease , Hofstra North Shore-LIJ School of Medicine , Manhasset
| | - Arif Dharsee
- Department of Medicine-Division of Infectious Disease , Hofstra North Shore-LIJ School of Medicine , Manhasset
| | - Juan Carlos Rico
- Department of Medicine-Division of Infectious Disease , Hofstra North Shore-LIJ School of Medicine , Manhasset
| | - Joseph McGowan
- Department of Biochemistry and Molecular Biophysics , Howard Hughes Medical Institute, Columbia University Medical Center , New York, New York
| |
Collapse
|
11
|
Lucena MI, Rico JC, Tarilonte MA, Andrade RJ, González-Correa JA, Sánchez de la Cuesta F. [Knowledge and attitudes of ambulatory patients regarding various aspects of pharmacologic treatment]. Rev Clin Esp 1990; 186:447-50. [PMID: 2247681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Recognizing the patients believes and attitudes towards their disease and treatment as well as facilitating basic information are essential for a satisfactory compliance. In this respect, and in order to know the state of things, personal interviews were carried out following a pre-established protocol and evaluating the degree of acceptance of information oriented to the outpatient. Two hundred and seven questionnaires were collected. Populations mean age was 50 years, 60% were women and there was a high percentage of illiterate patients or with only primary school level (69.8%), with a medium-low social status (98%). In general, they were aware of the indication of treatment (80%) although 56% of patients did not know the consequences of a poor control of their disease. Seventy eight percent wished to receive more information and 147 (96%) patients preferred the physician as the provider of it. The opinion regarding the information leaflets oriented towards the outpatient was unanimously favorable being the most interesting aspects those regarding the instructions on the use of drugs and adverse effects. The educational level was the factor influencing most significantly the patient's attitude. We conclude saying that in order to carry out a pharmacological treatment educational program it is necessary to evaluate the knowledge, needs and attitudes of the population towards whom it is directed.
Collapse
Affiliation(s)
- M I Lucena
- Departamento de Farmacología Clínica, Facultad de Medicina, Centros de Salud Palma-Palmilla, Málaga
| | | | | | | | | | | |
Collapse
|
12
|
Portilla J, López Aldeguer J, Massuti B, Rico JC, García Zarza A, Lacruz J, Caballero M. [Superior vena cava syndrome. Analysis of a series of 96 cases]. Rev Clin Esp 1987; 181:305-9. [PMID: 3432698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|
13
|
Collins J, Rico JC, Trudnowski RJ. Acupuncture and pain. AANA J 1976; 44:62-4. [PMID: 1044190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|